In Africa, new drugs are offered for national policy decisions tested in clinical trials involving not more than 6,000 patients without any long term follow up. Long term follow up data on how anti-malaria drugs work when delivered in routine setting is important for malaria control programmes to justify malaria treatment policy changes. INESS implements this study to create this missing final section of anti-malaria drug development pipeline on the continent.
The objectives of the project are;
1. Assessing the effectiveness of new malaria treatments and its determinants in real life health systems;
2. Evaluating safety of new malaria treatments through comprehensive pharmacovigilance in large populations and;
3. Tracking costs, effective coverage, and effects of new or alternative post-registration anti-malarial treatments.
